In anti-MuSK+ MG patients, classical treatment options, including acetylcholinesterase inhibitors, corticosteroid-sparing immunosuppressive treatments, and intravenous immunoglobulins (IVIg), are usually less effective than in anti AChR+ MG (37). This evidence concerns the gene MUSK and myasthenia gravis.